KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $364.0 million.

  • Esperion Therapeutics' Liabilities and Shareholders Equity rose 1588.79% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1073.37%. This contributed to the annual value of $343.8 million for FY2024, which is 6706.88% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Liabilities and Shareholders Equity of $364.0 million as of Q3 2025, which was up 1588.79% from $347.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Liabilities and Shareholders Equity ranged from a high of $381.6 million in Q4 2021 and a low of $205.8 million during Q4 2023
  • Its 5-year average for Liabilities and Shareholders Equity is $300.3 million, with a median of $312.8 million in 2022.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 3502.48% in 2022, then soared by 6706.88% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $381.6 million in 2021, then crashed by 35.02% to $247.9 million in 2022, then decreased by 17.0% to $205.8 million in 2023, then skyrocketed by 67.07% to $343.8 million in 2024, then grew by 5.87% to $364.0 million in 2025.
  • Its last three reported values are $364.0 million in Q3 2025, $347.1 million for Q2 2025, and $324.0 million during Q1 2025.